Drug Trial Radar · NCT07431281
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,130
Planned (sponsor's estimate)
Start
Feb 3, 2026
Primary completion
Aug 16, 2029
Study completion Oct 27, 2031
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer
Interventions
Sonesitatug vedotinDrug
Intravenous
RilvegostomigDrug
Intravenous
NivolumabDrug
Intravenous
CapecitabineDrug
Oral
5-FluorouracilDrug
Intravenous
OxaliplatinDrug
Intravenous
ZolbetuximabDrug
Intravenous
LeucovorinDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) (Cohort 1 and Cohort 2)Time frame: Up to approximately 5 years
- Overall Survival (OS) (Cohort 1)Time frame: Up to approximately 5 years
Locations
314 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Not yet recruiting
Research Site
Mobile, Alabama · Not yet recruiting
Research Site
Anchorage, Alaska · Not yet recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Springdale, Arkansas · Not yet recruiting
Research Site
Duarte, California · Not yet recruiting
Research Site
Fountain Valley, California · Recruiting
Research Site
Fullerton, California · Not yet recruiting
Research Site
Irvine, California · Recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Los Alamitos, California · Not yet recruiting
Research Site
Orange, California · Recruiting
Research Site
Walnut Creek, California · Recruiting
Research Site
Whittier, California · Not yet recruiting
Research Site
Denver, Colorado · Not yet recruiting
Research Site
Lone Tree, Colorado · Recruiting
Research Site
New Haven, Connecticut · Withdrawn
Research Site
Newark, Delaware · Not yet recruiting
Research Site
Washington D.C., District of Columbia · Withdrawn
Research Site
Fort Myers, Florida · Withdrawn
Research Site
Jacksonville, Florida · Not yet recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Orlando, Florida · Not yet recruiting
Research Site
St. Petersburg, Florida · Withdrawn
Research Site
West Palm Beach, Florida · Withdrawn
Research Site
Atlanta, Georgia · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Atlanta, Georgia · Withdrawn
Research Site
Macon, Georgia · Recruiting
Research Site
Newnan, Georgia · Not yet recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Niles, Illinois · Recruiting
Research Site
Zion, Illinois · Not yet recruiting
Research Site
Indianapolis, Indiana · Recruiting
Research Site
Waukee, Iowa · Not yet recruiting
Research Site
Lexington, Kentucky · Not yet recruiting
Research Site
Louisville, Kentucky · Not yet recruiting
Research Site
Silver Spring, Maryland · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Burlington, Massachusetts · Not yet recruiting
Showing 40 of 314 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.